Project Grant R01CA286443
Award Date
8/15/24
Completion Date
7/31/29
Dollars Obligated
$652K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $606,869 to Case Western Reserve University to conduct research on mechanisms of androgen receptor (AR) inverse agonists in advanced prostate cancer. The 5-year project, which began on July 5, 2024, aims to map the epigenetic mechanisms driving AR-mediated gene expression programs in metastatic castration-resistant prostate cancer (mCRPC) using sophisticated molecular and...
The National Cancer Institute (NCI) awarded a $393,401 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Washington State University (WSU) to develop a PSMA-targeted small-molecule dual drug conjugate (SMDDC) for treating metastatic castration-resistant prostate cancer (mCRPC) and other PSMA-positive malignancies. The project aims to assess the spatio-temporal cargo release of a PSMA-targeted SMDPC and determine the potency enhancement of a SMDDC bearing dual chemotherapeutic payloads...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Cancer Targeted Technology LLC for the development and validation of CTT2274, a novel PSMA-targeted small molecule prodrug for the treatment of advanced prostate cancer. The funding will enable the company to: (1) perform process development and optimization of the CTT2274 synthetic procedures, (2) assess the pharmacokinetics of CTT2274, and (3) determine the minimum...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $571,271 to the University of Texas Health Science Center at Houston to develop a novel PSMA-targeted drug conjugate for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The key objectives are to: (1) synthesize a PSMA-targeted drug conjugate using the microtubule inhibitor cryptophycin as the cytotoxic payload; (2) visualize and quantify the in vivo...
This $472,458 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to examine the role of the protein tyrosine phosphatase PTPN1 in driving therapy- and castration-resistant prostate cancer (T-CRPC) and the development of neuroendocrine prostate cancer (NEPC). The key objectives are to: 1) Investigate the regulation of PTPN1 gene expression by anti-androgen therapies and the reciprocal relationship between PTPN1, the androgen...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $624,001.00 to New York University School of Medicine to develop a novel class of drug candidates called multivalent peptoid conjugates (MPCs) that can effectively antagonize the androgen receptor (AR) in prostate cancer. The goal is to create MPC-based therapeutics that can stop the growth of prostate cancer cells, including those resistant to standard anti-androgen agents like...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $653,897 in funding to the University of Virginia to develop and evaluate novel small molecule inhibitors of the transcription factor ERG as a new approach for treating prostate cancer. The key objectives are to optimize the inhibitors for potency and specificity (Aim 1) and conduct preclinical evaluation in prostate cancer cell lines, patient tissue models, and patient-derived...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research into the regulation of the androgen receptor (AR) by the long non-coding RNA NXTAR in prostate cancer. The $549,357 award, with a performance period from August 2024 to July 2029, aims to determine the mechanism of NXTAR suppression in castration-resistant prostate cancers, synthesize PSMA-targeted nanoparticles containing NXTAR-N5 oligonucleotides and/or small molecule...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $545,078 to The Johns Hopkins University to conduct research aimed at enhancing the efficacy of radiopharmaceutical therapy for prostate cancer (PC) and renal cell carcinoma (RCC). The research will systematically evaluate the impact of PSMA-based radiopharmaceutical therapy (PSMA-RPT) on glutamine metabolism, a key metabolic pathway in these cancers. The project will assess the effects...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that leverages tumor-associated proteases to selectively deliver a potent cytotoxin into cancer cells. The goal is to create a targeted therapeutic strategy to improve treatment outcomes for metastatic and recurrent solid tumors, including ovarian, lung, and colon cancers. Key elements of the...